The SBIR funding will be used to complete the IND-enabling steps and initiate clinical trials of our anti-TNFR2 antibody, BIR2101 https://www.businesswire.com/news/home/20211213005260/en/BITT-Announces-NIH-SBIR-Award-and-New-Board-Member
TNFR2 as Therapeutic Target in Immunotherapy | ITT @DovePress https://www.dovepress.com/tnfr2-role-in-cancer-immunology-and-immunotherapy-peer-reviewed-fulltext-article-ITT Another great paper from Dr. Chen and his team #tnfr2
Boston Immune Technologies and Therapeutics Raises $10M Series A Financing | Business Wire https://www.businesswire.com/news/home/20210317005784/en/Boston-Immune-Technologies-and-Therapeutics-Raises-10M-Series-A-Financing#.YFJXIn-ETy4.twitter
A TNFR2-hnRNPK axis promotes primary liver cancer development via activation of YAP signaling in hepatic progenitor cells https://cancerres.aacrjournals.org/content/early/2021/02/19/0008-5472.CAN-20-3175
Selexis and Boston Immune Technologies and Therapeutics (BITT) Enter Service Agreement to Advance BITT’s Lead TNFR2 Oncology Candidate | Business Wire https://www.businesswire.com/news/home/20210309005147/en/Selexis-and-Boston-Immune-Technologies-and-Therapeutics-BITT-Enter-Service-Agreement-to-Advance-BITT%E2%80%99s-Lead-TNFR2-Oncology-Candidate#.YEd6MFxau9Y.twitter